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Background: Up to 20% of patients with inflammatory bowel disease (IBD) who are refractory to thiopurine therapy preferentially produce 
6-methylmercaptopurine (6-MMP) at the expense of 6-thioguanine nucleotides (6-TGN), resulting in a high 6-MMP:6-TGN ratio (>20). The 
objective of this study was to evaluate whether genetic variability in guanine monophosphate synthetase (GMPS) contributes to preferential 
6-MMP metabolizer phenotype.
Methods: Exome sequencing was performed in a cohort of IBD patients with 6-MMP:6-TGN ratios of >100 to identify nonsynonymous single 
nucleotide polymorphisms (nsSNPs). In vitro assays were performed to measure GMPS activity associated with these nsSNPs. Frequency of the 
nsSNPs was measured in a cohort of 530 Caucasian IBD patients.
Results: Two nsSNPs in GMPS (rs747629729, rs61750370) were detected in 11 patients with very high 6-MMP:6-TGN ratios. The 2 nsSNPs 
were predicted to be damaging by in silico analysis. In vitro assays demonstrated that both nsSNPs resulted in a significant reduction in GMPS 
activity (P < 0.05). The SNP rs61750370 was significantly associated with 6-MMP:6-TGN ratios ≥100 (odds ratio, 5.64; 95% confidence interval, 
1.01–25.12; P < 0.031) in a subset of 264 Caucasian IBD patients.
Conclusions: The GMPS SNP rs61750370 may be a reliable risk factor for extreme 6MMP preferential metabolism.
Key Words:  azathioprine, 6-mercaptopurine, 6-thioguanine nucleotides (6-TGN), 6-methylmercaptopurine (6-MMP), guanosine  monophosphate 
synthetase (GMPS)
INTRODUCTION
Azathioprine (AZA) and 6-mercaptopurine (6-MP) 
are prodrugs that undergo a complex metabolism result-
ing in the generation of several inactive products and the 
active 6-thioguanine nucleotide (6-TGN) metabolites and 
hepatotoxic metabolite 6-methylmercaptopurine (6-MMP) 
(Fig.  1).1 Concentrations of 6-TGN >235 pmol/8  ×  108 red 
blood cells (RBCs) have been associated with disease remis-
sion in IBD, whereas concentrations of 6-MMP exceeding 
5700 pmol/8 × 108 have been associated with an increased risk 
of hepatotoxicity.2 Poppe et  al.3 demonstrated that 1 of the 
6-TGNs, 6-thioguanine triphosphate (6-TGTP) (Fig. 1), con-
tributes markedly to the overall immunosuppressive effect of 
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thiopurine therapy by binding to the small guanosine triphos-
phatase (GTPase) RAC1 (Ras-related C3 botulinum toxin 
substrate 1) on CD28 co-stimulation in CD4+ T cells. Binding 
of 6-TGTP to RAC1 blocks Vav guanine nucleotide exchange 
factor (Vav) exchange activity, leading to the disruption of the 
Vav1-Rac1 signalling cascade and a therapeutic reduction in 
inflammation (Fig. 1).4
Up to 20% of patients on thiopurine therapy preferen-
tially produce 6-MMP, at the expense of 6-TGN production, 
resulting in a high 6-MMP:6-TGN ratio (>20) and increased 
risk of hepatotoxicity and ineffectiveness of thiopurine ther-
apy.5 Several authors have proposed that this preferential 
6-MMP producer phenotype is due to elevated thiopurine 
S-methyltransferase (TPMT) activity. However, the vast major-
ity (>95%) of patients who exhibit this phenotype seem to have 
normal or intermediate TPMT activity. In 51 patients with IBD, 
Dubinsky et al.2 found that the baseline RBC TPMT activity 
did not differ between patients who responded to 6-mercapto-
purine and patients who preferentially metabolized 6-mercap-
topurine to 6-MMP.2 More recently, a survey of 1879 patients, 
of which 74% had a diagnosis of IBD, found that 19% (349) 
had a 6-MMP:6-TGN ratio >20, and the mean RBC TPMT 
activity of these patients was similar to the activity in patients 
with a ratio <20.5 Only 3% of patients with a high 6-MMP:6-
TGN ratio were found to have ultrahigh TPMT enzyme activ-
ity.5 Taken together, these studies suggest strongly that high 
TPMT enzyme activity is not the primary cause of preferential 
6-MMP production.
At present, only 3 studies have investigated the possibility 
that genetic variation other than in TPMT may contribute to high 
6MMP:6TGN ratios. In the first study, 20 preferential 6-MMP 
metabolizers and 17 IBD patients with 6-MMP:6-TGN ratios of 
<20 were screened for sequence variants in inosine-5-monophos-
phate dehydrogenase 1 (IMPDH1) and IMPDH2. A 9-bp inser-
tion identified in the promoter of IMPDH1 abolished a cAMP 
response element (CRE) and was found to significantly reduce 
gene expression in vitro (P < 0.001).6 However, this variant was 
only found in 1 of the 20 preferential 6-MMP producers that had 
a 6-MMP:6-TGN ratio of ≥100. Furthermore, no other genetic 
variants found in this study were associated with preferential 
FIGURE 1. Thiopurine drug metabolism. The pro-drug AZA is quickly converted, via a nonenzymatic reaction, to 6-MP, which undergoes extensive 
metabolism via 3 competing pathways, mediated by xanthine dehydrogenase (XDH), TPMT, and HPRT, respectively. The pathway mediated by XDH 
produces the inactive metabolite 6-thiouric acid. TPMT catalyses the production of a second inactive metabolite (6-MMP). The HPRT pathway gen-
erates 6-TIMP. Once formed, 6-TIMP may be transformed into either 6-TGN by the rate-limiting IMPDH and GMPS, methylated into 6-MMP by TPMT, 
or phosphorylated to 6-thio-ITP. 6-MMP, 6-TGNs, and 6-thio-ITP are all active metabolites. In normal cells, the accumulation of 6-thio-ITP to toxic 
concentrations is prevented by ITPAse, which converts 6-thio-ITP back to 6-TIMP. The principal cytotoxic mechanism of thiopurines is the incorpora-
tion of 6-TGNs into DNA and RNA. Abbreviations: 6-MeMP, 6-methylmercaptopurine; 6-MeTGMP, 6-methylthioguanine monophosphate; 6-MeTITP, 
6-methylthioinosine triphosphate; 6-TGDP, 6-thioguanine diphosphate; 6-TGMP, 6-thioguanine monophosphate; 6-TIDP, 6-thioinosine diphosphate; 
6-TITP, 6-thioinosine triphosphate; 6-TU, 6-thiouric acid; 6-TXMP, 6-thioxanthosine monophosphate; 8-OHTG, 8-hydroxythioguanine; AOX1, aldehyde 
oxidase 1; GST, glutathione S-transferase; ITPAse, inosine triphosphate pyrophospatase.
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6-MMP production, suggesting that if  genetic variability in 
IMPDH does contribute to this phenotype, it does so only infre-
quently. The second study compared gene expression in 10 IBD 
patients who had 6-MMP:6-TGN ratios of >20 with expression 
profiles in 11 patients with ratios <20.7 Microarray and quanti-
tative real-time polymerase chain reaction (RT qPCR) analyses 
identified 18 genes that were significantly associated with high 
ratios. Nine of the identified genes play no known role in the 
purine pathway. Of the genes known to be related to the purine 
pathway, patients with 6-MMP:6-TGN ratios of >20 showed 
lower expression levels of microsomal glutathione S-transferase 
2 (MGST2), TPMT, and NME6, but higher expression levels of 
IMPDH2 and NT5E compared with patients with 6-MMP:6-
TGN ratios of ≤4.7 This study did not explore whether these 
differences in expression were due to genetic variants. The third 
and most recent study employed exome sequencing and com-
parative genomic hybridization to identify genetic variants 
that may contribute to extreme 6-MMP metabolism. Despite 
detailed analysis, the authors were unable to identify any con-
vincing candidate single nucleotide polymorphisms (SNPs) or 
copy variants that could explain the 6-MMP preferential metab-
olizer phenotype.8
Azathioprine undergoes extensive metabolism via 3 com-
peting pathways (Fig. 1). The hypoxanthine guanine phosphor-
ibosyl transferase (HPRT) pathway generates 6-thioinosine 
monophosphate (6-TIMP). Once formed, 6-TIMP may be 
transformed into either thioguanine nucleotides (6-TGN) by the 
rate-limiting IMPDH and guanine monophosphate synthetase 
(GMPS), 6-MMP by TPMT, or phosphorylated to 6-thio-in-
osine triphosphate (6-thio-ITP) (Fig.  1). As GMPS catalyses 
the final step in the generation of 6-TGNs (Fig. 1), any genetic 
variation that impairs GMPS function would reduce 6-TGN 
production, thereby skewing AZA metabolism and potentially 
resulting in a preferential 6-MMP metabolizer phenotype.
The overall aim of our study was to screen patients with 
IBD for the potential existence of loss of function nonsynon-
ymous single nucleotide polymorphisms (nsSNPs) in GMPS, 
which could contribute to preferential 6-MMP metabolism. 
Our a priori hypothesis was that such polymorphisms were 
more likely to exist in patients who had an extreme preferential 
6-MMP metabolizer phenotype. For the purpose of this study, 
we defined extreme preferential 6-MMP metabolizers as indi-
viduals with a 6-MMP:6-TGN ratio (>100).9
METHODS
Study Participants
Participants included 530 IBD patients on current or pre-
vious thiopurine treatment, under the care of the IBD services at 
the Royal Adelaide Hospital and Flinders Medical Centre (South 
Australia), Royal Brisbane and Women’s Hospital (Queensland, 
Australia), Fremantle Hospital (Western Australia), St. 
Vincent’s Hospital (Melbourne, Victoria, Australia), and the 
VU University Medical Center (Amsterdam, the Netherlands). 
Patients were considered to fit the definition of preferential 
6-MMP producers if  they exhibited normal or low TPMT activ-
ity and had a ratio of 6-MMP to 6-TGN concentrations within 
red blood cells (RBCs) ≥20.10 Controls (n = 735) were older than 
age 18 years and had no history of any inflammatory disease. 
The control sample set was recruited from the Otago region of 
New Zealand, as described in detail elsewhere.11 All study partic-
ipants were unrelated and of Caucasian ethnicity. Each partici-
pant was recruited with informed consent, and ethical approval 
for this study was obtained from the relevant Ethics Committee 
associated with each recruiting center.
Measurement of 6-TGN and 6-MMP in the 
Peripheral Blood of IBD Patients
Blood (5  mL) was collected in a heparinized tube and 
centrifuged to isolate RBCs. The RBCs were washed twice in 
2 volumes of saline, counted to allow normalization of 6-TGN 
and 6-MMP concentrations to 8 × 108 RBCs, and then frozen. 
The concentrations of 6-TGN and 6-MMP in the peripheral 
blood of each IBD patient were determined using HPLC, as 
previously described.12
DNA Extraction and Exome Sequencing
DNA samples were collected from the peripheral blood 
of IBD patients and controls using guanidium isothiocyanate 
extraction, resuspended in Tris-EDTA buffer (pH 8.0), and 
stored at –20ºC.13 Exome sequencing was performed on the 
DNA of 11 IBD patients using an Illumina HiSeq 2000. As per 
our a priori hypothesis, all patients selected for exome sequenc-
ing had 6-MMP:6-TGN ratios of >100 and a TPMT*1/*1 
genotype. Only these patients with a very high metabolite ratio 
were selected for exome sequencing to maximize the chance 
of detecting relevant new SNPs. Sequences were aligned using 
BWA to the human GRCh37 reference.14 The Genome Analysis 
Toolkit (GATK)15 was applied for base quality score recalibra-
tion, insertion/deletion (Indel) realignment, duplicate removal, 
and SNP and Indel discovery, and genotyping across all sam-
ples was performed simultaneously using standard hard filter-
ing parameters or variant quality score recalibration.16 The 
web-based genome analysis tool Galaxy17–19 was used to extract 
exons of GMPS to identify SNPs discovered by the GATK.
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and 
SIFT (http://sift.jcvi.org/) were used to predict the functional 
impact of nsSNPs identified by GATK. nsSNPs predicted to 
be damaging by both these programs were confirmed by direct 
sequencing.
In Vitro Analysis of the Functional Impact of 
Selected GMPS nsSNPs on 6-TGN Production
A full-length GMPS (NM_003875) human cDNA 
open reading frame clone in a pCMV6 vector (OriGene 
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Technologies, MD) was used as the wild-type GMPS and as a 
template to generate mutant isoforms. Site-directed mutagen-
esis was used to introduce point mutations at +1583  bp and 
+1660 bp  upstream of the GMPS start codon. PWO polymerase 
(Roche) was used with the following oligonucleotides in PCR 
 reactions, as per previously described20: rs61750370 (+1583bp): 
Forward, 5’-GTCGTTCCTACAGTTCCGTGTGTGGA-3’; 
Reverse, 5’-GAGATTCCACACACGGAACTGTAGGA-3’; 
rs747629729 (+1660bp): Forward, 5’- 
CTTATACCTCGCATGGGTCACAACGT - 3’; Reverse, 
5’-TGTTAACGTTGTGACCCATGCGAGGT-3’. Mutated 
sites are shown in bold and underlined. Thermal cycling condi-
tions were as follows: 2 minutes at 94°C (initial denaturation); 
35 cycles of 30 seconds at 94°C, 30 seconds at 55°C–65°C, 40 
seconds at 72°C; and a final extension of 2 minutes at 72°C.
HEK-293 cells were maintained in DMEM contain-
ing 10% fetal calf  serum in 75-cm2 flasks at 37°C (5% CO2). 
GMPS isoforms were transfected into HEK-293 cells in 6-well 
plates seeded at 5 × 55 cells/well 24 hours before transfection. 
Transfections were performed using FuGENE6, as previously 
described,21 and a control transfection was performed using 
empty pCMV6 vector. After 24-hour transfection, the cells 
were exposed to 50 µM 6-Mercaptopurine monohydrate (6-MP; 
Sigma-Aldrich Company Ltd, Poole, UK) for 6 hours. The cells 
were subsequently washed with 2 mL ice-cold PBS and resus-
pended by adding 750 µL H20 containing 1mM DTT through 
mechanical scarping. The resuspended cells were transferred 
into the –80°C freezer for 20 minutes and then thawed at RT 
for 20 minutes for 2 cycles. The cells were then acid-hydrolyzed 
by adding 150 μL 60% perchloric acid, vortexed for 20 seconds, 
placed in an ice bath for 10 minutes, and spun down at 13,000 g 
for 15 minutes. The supernatant was then carefully removed 
from the cell debris and placed into a 1.5-mL tube, which was 
then boiled for 45 minutes and stored at –80°C.
6-TGN concentrations from cell lysates were each deter-
mined separately by high-performance liquid chromatography 
(Beckman Coulter) with UV detection; 6-TGN concentrations 
for each sample were expressed as µM and were calculated 
through a standard calibration curve using 6-TGN (Sigma). The 
mobile phase for 6-TGN included 98% H2O, 2% acetonitrile, 
20 mM potassium phosphate buffer, and 100 mM triethylamine. 
The retention time for 6-TGN was determined at ~6–7 minutes.
Genotyping of GMPS nsSNPs
Study participants were genotyped for GMPS nsSNPs 
rs61750370 and rs747629729 using TaqMan SNP genotyp-
ing assays following the manufacturer’s instructions (Applied 
Biosystems, Foster City, CA, USA). Briefly, the assays were per-
formed in a total reaction volume of 5 µL containing 2.5 µL of 
2× TaqMan Universal Master Mix (Roche Molecular Systems 
Inc, Branchburg, NJ, USA), 0.25 µL of 20× SNP genotyping 
assay, and 12 ng of genomic DNA. The PCR was performed 
in 384-well format on a Roche LightCycler 480 real-time PCR 
system, with an activation step of 10 minutes at 95°C, followed 
by 40 cycles of denaturation (15 seconds at 92°C) and annealing/
extension (1 minute at 60°C). Genotypes were assigned using the 
end point genotyping analysis software. A  sequence-validated 
control was included in each batch of genotyping. To check the 
accuracy of the genotype assignment, genotyping was repeated 
on 10% of samples. The concordance between original and 
repeat genotypes was 100%. The web-based analysis program 
SHEsis (http://analysis2.bio-x.cn/myAnalysis.php)22 was used to 
check for deviations in Hardy-Weinberg Equilibrium (HWE).
RESULTS
Measurement of 6-TGN and 6-MMP 
Concentrations in IBD Patients
Of the 530 IBD patients enrolled in the study, RBC 
6-TGN and 6-MMP concentrations were measured in 275 IBD 
patients. A  total of 172 patients had 6-MMP:6-TGN ratios 
≥20, of whom 34 had ratios of ≥100. Eleven of the patients who 
had ratios of ≥100, representing all recruitment centers, under-
went exome sequencing. Resource constraints limited further 
sequencing (see Table 1 for demographic details).
Identification and Characterization of nsSNPs
Exome sequencing was successfully completed in all 11 
patients. A total of 18 intronic SNPs, 1 synonymous SNP, and 
2 nsSNPs (rs61750370 and rs747629729) were found in GMPS. 
Both nsSNPs were predicted to be damaging by PolyPhen-2 
and SIFT. These nsSNPs were validated by Sanger sequencing. 
Figure 2 shows how GMPS protein sequences are highly con-
served across species.
In Vitro Analysis of 6-TGN Production by GMPS 
Variants Using HPLC
The functional effect of the GMPS nsSNPs on 6-TGN 
production was evaluated using a HEK-293 cell model and 
TABLE  1: Demographics of 11 Exome-Sequenced 
Patients With 6-MMP/6-TGN Ratio >100
No. Unless Otherwise Stated
Age, median (range), y 37.5 (24–51) 
IBD type 9 CD, 2 UC
Thiopurine type 8 on 6-MP, 3 on AZA
Hepatotoxicitya 6
Severe nauseaa 2
Allopurinol used successfullya 6
aHepatotoxicity: liver function test results >3× normal; severe nausea: sufficient 
to withdraw therapy; allopurinol used successfully: resulting in correction of the 
6-MMP/6-TGN ratio.
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HPLC analysis. Analysis of variance revealed a significant dif-
ference in 6-TGN production between wild-type and variants 
of the GMPS enzyme (P < 0.0001; F = 48.77; RSq = 0.8667). 
A  paired t test comparing mean 6-TGN production found 
a significant reduction in 6-TGN production by the SNP 
rs61750370 compared with wild-type (P < 0.0001) and the SNP 
rs747629729 compared with wild-type (P < 0.05) (Fig. 3).
Frequency of GMPS nsSNPs in Controls and IBD 
Patients
Seven hundred thirty-five healthy Caucasian controls 
were genotyped for GMPS nsSNPs. The minor allele fre-
quency of GMPS SNP rs61750370 was 0.01 in this control set. 
The GMPS SNP rs747629729 was not detected in any of the 
controls.
Excluding the 11 patients who underwent exome sequenc-
ing, 519 IBD patients were genotyped for the 2 GMPS nsSNPs. 
A total of 12 IBD patients were heterozygous for the GMPS 
SNP rs61750370 (minor allele frequency, 0.023). No patient 
was homozygous or heterozygous for the second GMPS SNP 
rs747629729.
Metabolite ratios were available for 264 patients who had 
not been exome-sequenced. In this subset, 6 patients were hete-
rozygous for GMPS rs61750370. Association testing found that 
the GMPS nsSNP rs61750370 was significantly associated with 
6-MMP:6-TGN ratios ≥100 (odds ratio, 5.64; 95% confidence 
interval, 1.01–25.12; P = 0.031), but not with ratios 6-MMP:6-
TGN ≥20 (P = 0.579) (Table 2).
DISCUSSION
To our knowledge, the current study is only the fourth 
to explore the possibility that variation in genes other than 
TPMT may contribute to the preferential 6-MMP metabolizer 
phenotype. The major finding of our study is the identification 
of nsSNPs rs61750370, 1583A>C, and Y528S in exon 13 of the 
GMPS gene, which was shown to significantly reduce enzyme 
activity in vitro and was significantly associated with extreme 
preferential 6-MMP production (6-MMP:6-TGN ratios ≥100).
Guanine monophosphate synthetase (EC 6.3.5.2) is a glu-
tamine-dependent amidotransferase consisting of a single struc-
tural domain formed by the C-terminus and 2 catalytic domains, 1 
required for glutaminase activity and 1 for pyrophosphate-ATPase 
(PP-ATPase) activity.23, 24 In addition to mediating the final step in 
the generation of 6-TGNs (Fig. 1), GMPS also plays a key role in 
de novo purine synthesis. As an ample supply of purines is essential 
for many life processes, it is not surprising that much of the amino 
acid sequence of GMPS is highly conserved across prokaryotic and 
eukaryotic species.25, 26 The SNP rs61750370 results in the substitu-
tion of a tyrosine residue for a serine at position 528 in the GMPS 
protein. Alignment of the human GMPS sequence against GMPS 
sequences from other species demonstrates that tyrosine 528 is 
conserved across mammals (Fig. 2). Tesmer et al.24 elucidated the 
crystal structure of Escherichia coli GMPS. This bacterial GMPS 
exists as a tetramer and is hypothesized to coordinate the activity of 
its 2 catalytic domains through a series of conformational changes 
that bring the active sites of the 2 domains into close juxtaposition. 
Integral to these movements are 2 dimerization domains that are 
formed from the C termini of the 4 GMPS subunits that make up 
the tetrameric protein. The dimerization domains assist in forming 
the ATP-binding site of the ATP-PPase domain.24 It is possible 
that amino acid changes within the dimerization domain, such as 
the 1 described in this study, may reduce the catalytic functioning 
of GMPS by altering the conformation of the PP-ATPase domain 
and thereby the binding and turnover of ATP. In contrast to E. coli 
GMPS, there is some evidence to suggest that the human enzyme 
exists as a monomer, rather than a tetramer.23 However, given the 
degree of amino acid conservation observed across species (Fig. 2), 
FIGURE 2. Alignment of GMPS protein sequences. The amino acid residue altered by GMPS SNP rs61750370 (Y528S) is highlighted in the human var-
iant and human reference protein sequence. The alignment of the corresponding protein sequences from other species shows the degree to which 
the affected amino acid residues are conserved.
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it is likely that the C-terminal domain still plays an important role 
in the functioning of human GMPS. This assertion is supported by 
data related to C-terminal mutations in arginiosuccinate synthetase 
(ASS). These mutations cause the rare autosomal recessive disorder 
classical citrullinemia, which results in accumulation of citrulline in 
the blood and urine.27 ASS is a monomeric amidotransferase that 
is closely related to GMPS and catalyzes the third step in the urea 
cycle. Mutations located in the C-terminal domain are believed to 
impair enzyme activity by compromising the tertiary and quater-
nary structure of the ASS.27 Further evidence that the GMPS nsSNP 
rs61750370 may impact enzyme function comes from a recent 
exome array study of the plasma metabolome. This study found 
that rs61750370 was significantly associated with xanthosine levels 
in both the Framingham Heart Study cohort (P = 2.8 × 10-7) and the 
Atherosclerosis Risk in Communities Study cohort (P = 6 × 10-4).28
Although our study has found a significant association 
of the GMPS nsSNP rs61750370 with extreme preferential 
6-MMP metabolism, this nsSNP is a rare polymorphism that 
was only found in 6 of the 264 IBD patients in whom metabolite 
ratios were determined and who were not included in the initial 
exome sequencing. Of these 6 patients, 3 had 6-MMP:6-TGN 
ratios <20. This finding indicates that although GMPS nsSNP 
rs61750370 seems to be a risk factor for extreme preferential 
6-MMP metabolism, it is insufficient alone to cause this phe-
notype, and other factors contribute to determining 6-MMP 
metabolizer phenotype. These factors are likely to be a com-
bination of genetic and environmental. It is conceivable that 
other rare nsSNPs and SNPs in noncoding regions of GMPS, 
and genetic variants in other enzymes such as IMPDH, interact 
with environmental factors to determine whether an individual 
is at risk of being a preferential 6-MMP metabolizer.
Our study has a number of important limitations. 
First, the study participants were all of Caucasian ethni-
city. Therefore, it is unknown whether the GMPS nsSNP 
rs61750370 is a potential risk factor for preferential 6-MMP 
metabolism in other races. However, dbSNP genotyping data, 
albeit limited for rs61750370, suggest that the minor allele of 
this nsSNP occurs at a comparable frequency in South East 
Asian, Africa, and American populations, raising the possibil-
ity of a similar association between this SNP and thiopurine 
metabolism in other races. Second, only 11 patients underwent 
exome sequencing of GMPS. We cannot rule out the possibility 
that further rare nsSNPs with functional relevance to thiopu-
rine metabolism exist and would have been identified if  more 
patients were sequenced. Additionally, as we opted for exome 
sequencing, our study was unable to detect functional SNPs in 
noncoding regions. Finally, metabolite ratios were only meas-
ured in 275 of the 530 IBD patients, thereby limiting the power 
of our study. Taking into account the limitations of the cur-
rent study, we recommend that future research into preferen-
tial 6-MMP metabolism is conducted on larger cohorts using 
full genome sequencing to maximize the ability to detect rare 
but potentially significant SNPs in both coding and noncoding 
regions of GMPS.
On average, there is a delay of 8–12 weeks between an 
IBD patient commencing thiopurine medication and receiving 
some therapeutic benefit,22 and some patients may not receive 
TABLE 2: Allele and Genotype Frequencies of GMPS SNP rs61750370 in Patients With Inflammatory Bowel Disease 
Stratified According to 6-MMP:6-TGN Ratiosa
6-MMP:6-TGN Ratio
Genotype MAF
Allelic P OR (95% CI)T,T T,G G,G G
≥20 158 (0.98) 3 (0.02) 0 (0.00) 3 (0.01) 0.579 0.64 (0.13–3.18)
<20 100 (0.60) 3 (0.03) 0 (0.00) 3 (0.02)
≥100 21 (0.91) 2 (0.09) 0 (0.00) 2 (0.04) 0.031 5.64 (1.01–25.12)
<100 237 (0.60) 4 (0.02) 0 (0.00) 4 (0.01)
aPatients who were exom- sequenced were excluded from this analysis.
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FIGURE 3. HPLC analysis of 6-TGN production by wild-type and variant 
GMPS isoforms. HEK293 cells were transfected with pCMV6 vector con-
taining the human wild-type GMPS gene, or the variants rs61750370 
and rs747629729, and then exposed to 50 µM 6-MP. Production of 
6-TGN by the 3 GMPS isoforms was measured by HPLC, compared with 
the empty pCMV6 vector (EV), which was set at 100%. 6-TGN produc-
tion was reduced significantly for both gene variants compared with 
wild-type.
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benefit for up to 6  months.29 Early prediction of treatment 
failure or hepatotoxicity would therefore save valuable time 
in establishing effective treatment. Furthermore, in anti-TNF 
therapy, it has been shown that thiopurine co-medication has a 
beneficial synergistic effect,30 but there remains a risk of hepato-
toxicity in patients with preferential 6-MMP production. As it 
becomes clearer over time which SNPs significantly alter thiop-
urine metabolism, there may be merit in prospective genotyping 
of patients and including GMPS SNP rs61750370 (1583A>C) 
to identify a small but noteworthy percentage of patients who 
are at risk of reduced efficacy or hepatotoxicity from thiopu-
rine therapy, leading to untimely and avoidable discontinuation 
of this therapy. A number of studies have shown that patients 
with IBD who have a 6-MMP:6-TGN ratio ≥20 on thiopurine 
treatment have had correction of the ratio and improved clin-
ical outcome with co-prescription of allopurinol.31–34 Favorable 
change in the ratio with co-prescribed allopurinol has occurred 
in every patient studied so far, suggesting that co-prescription 
of allopurinol overcomes preferential 6-MMP production 
in the patients with GMPS loss-of-function SNPs by caus-
ing indirect inhibition of TPMT, thus forcing the metabolism 
toward 6-TGN production,35 although this is unproven as yet. 
Similarly, some European experts suggest that the use of a res-
cue thiopurine derivative, thioguanine, may be an alternative 
strategy in patients with this unfavorable thiopurine profile.36 
Although only IBD patients were included in this study, it is 
likely that other disease cohorts will display similar thiopurine 
metabolite profiles related to the newly identified SNPs.
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